Placebo Control

Maybe those pesky sites are good for something after all.  It's been six years since Pfizer boldly announced the launch of its "...

[Originally posted on First Patient In ] In my experience, most clinical trials do not suffer from significant retention issues. This is ...

It is a surprisingly common peril among analysts: we don’t have the data to answer the question we’re interested in, so we answer a related ...

The decade following passage of FDAAA has been one of easing standards for drug approvals in the US, most notably with the advent of “break...

Jerry Matczak passed away suddenly last Thursday at the much-too-young age of 54. I can say, without exaggeration, that Jerry embodied pr...